Cancer NetworkOriginal article
<![CDATA[Savolitinib Combo Boosts PFS in First-Line EGFR-Mutant NSCLC Trial]]>
Phase 3positivesavolitinibosimertinibPositive
AI Analysis
Summary
Savolitinib combined with osimertinib demonstrated significantly improved progression-free survival compared to osimertinib monotherapy as first-line treatment in the Phase 3 SANOVO trial for EGFR-mutant non-small cell lung cancer.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Savolitinib/osimertinib significantly improved progression-free survival vs osimertinib alone in SANOVO trial
Importance:7/10
Sentiment:
0.75
oncologyNSCLCPhase 3EGFR mutationcombination therapyprogression-free survival
Related Companies
Read the original article
Published by Cancer Network on August 31, 2026 4:00 PM